Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
PHOENIX BIOTECH ACQUISITION CORP. | Director | Class A Common Stock | 5.83K | $58.3K | $10.00 | Feb 14, 2024 | Direct |
eFFECTOR Therapeutics, Inc. | Director | Common Stock | 9.05K | $5.49K | $0.61 | Sep 9, 2023 | Direct |
Aptose Biosciences Inc. | Former Director | Director Stock Option (Right to Buy) | 50K | Jan 18, 2022 | Direct | ||
PhaseBio Pharmaceuticals Inc | Director | Common Stock | 3.75K | May 19, 2023 | Direct | ||
eFFECTOR Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 800 | Jun 13, 2024 | Direct | ||
CymaBay Therapeutics, Inc. | Director | Employee Stock Option (right to buy) | 0 | Mar 22, 2024 | Direct | ||
PhaseBio Pharmaceuticals Inc | Director | Restricted Stock Units | 0 | May 19, 2023 | Direct | ||
ZOGENIX, INC. | Director | Stock Option (Right to Buy) | 0 | $26.09 | Mar 7, 2022 | Direct |